Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Executive Summary

• The United States Patent and Trademark Office granted Neurothera Labs Inc. a U.S. patent covering its proprietary combination of approved antibiotics with cannabinoids (THC, CBD) and related compounds.
• This U.S. patent adds to existing patents in the U.S. and Europe, strengthening global IP protection for Neurothera’s antimicrobial‑potentiating platform aimed at combating antibiotic‑resistant bacteria such as MRSA.
• The company highlights pre‑clinical data showing synergistic enhancement of antibiotic activity, positioning the technology as a potential “antimicrobial‑sparing” solution in a market projected to reach ~$58 billion by 2026.

Key Details

• Patent Grant: U.S. patent issued for compositions and methods that combine established antibiotics with cannabinoids (THC, CBD) and, in some embodiments, N‑acylethanolamines (e.g., palmitoylethanolamide).
• Global IP Portfolio: The new U.S. patent joins previously granted family patents in the United States and Europe, providing broader protection for the platform worldwide.
• Pre‑clinical Evidence: Studies in regulatory‑compliant models demonstrated that cannabinoid‑antibiotic combinations increase antimicrobial activity against Gram‑positive resistant pathogens (e.g., MRSA), potentially restoring efficacy of antibiotics that are ineffective as monotherapy.
• Therapeutic Rationale: Leveraging long‑term safety data of existing antibiotics, the platform aims to reduce reliance on new antibiotic development, lower toxicity risks, and mitigate resistance emergence.
• Market Context: Global antibiotics market projected at ~US$58 billion in 2026 (Mordor Intelligence). MRSA accounted for ~130,000 deaths worldwide in 2021 (The Lancet), underscoring the unmet need for innovative solutions.
• Strategic Positioning: Neurothera positions its platform as an “antimicrobial‑sparing” approach that could diminish the constant demand for novel antibiotics and address safety concerns associated with current therapies.
• Forward‑Looking Statements: The release contains forward‑looking statements regarding the potential efficacy, safety, IP strength, and commercial prospects of the cannabinoid‑antibiotic platform; risks include reliance on pre‑clinical data, regulatory uncertainties, patent enforceability, need for additional capital, and market dynamics.

Notable Quotes

• “The patented technology combines well‑established antibiotics with cannabinoids, demonstrating in pre‑clinical studies an enhanced antimicrobial activity that could restore the effectiveness of existing drugs against resistant Gram‑positive pathogens such as MRSA.” – Neurothera Labs Inc. (press release)